Float Short %

11.9

Margin Of Safety %

Put/Call OI Ratio

0.51

EPS Next Q Diff

-0.2

EPS Last/This Y

0.22

EPS This/Next Y

-0.42

Price

85.36

Target Price

149.89

Analyst Recom

Performance Q

-27.67

Relative Volume

1.31

Beta

0.98

Ticker: PCVX

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	PCVX	86.17	0.69	0.00	12348
2024-12-20	PCVX	86.59	0.67	2.33	12250
2024-12-23	PCVX	87.03	0.58	1.02	10893
2024-12-24	PCVX	85.91	0.57	0.00	11046
2024-12-26	PCVX	85.68	0.58	0.00	11190
2024-12-27	PCVX	80.88	0.58	0.07	11180
2024-12-30	PCVX	81.97	0.57	17.89	11160
2024-12-31	PCVX	81.88	0.58	0.11	11255
2025-01-02	PCVX	83.33	0.53	5.00	10884
2025-01-03	PCVX	84.81	0.53	999.99	10895
2025-01-06	PCVX	86.05	0.54	999.99	10905
2025-01-07	PCVX	87.36	0.51	0.50	10718
2025-01-08	PCVX	81.05	0.51	1.63	10719
2025-01-09	PCVX	81.06	0.51	0.13	10719
2025-01-10	PCVX	81.13	0.41	0.04	11524
2025-01-13	PCVX	81.07	0.32	0.00	13451
2025-01-14	PCVX	78.21	0.32	0.34	13421
2025-01-15	PCVX	89.32	0.28	1.73	13833
2025-01-16	PCVX	87.82	0.55	1.14	20008
2025-01-17	PCVX	85	0.51	1.05	21073
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	PCVX	86.18	42.6	-	-3.96
2024-12-20	PCVX	86.57	42.6	-	-3.96
2024-12-23	PCVX	87.08	44.3	-	-3.92
2024-12-24	PCVX	85.91	44.3	-	-3.92
2024-12-26	PCVX	85.78	44.3	-	-3.92
2024-12-27	PCVX	80.91	44.3	-	-3.92
2024-12-30	PCVX	82.00	44.3	-	-3.92
2024-12-31	PCVX	81.85	44.3	-	-3.92
2025-01-02	PCVX	83.32	44.3	-	-3.92
2025-01-03	PCVX	84.85	44.3	-	-3.92
2025-01-06	PCVX	86.04	44.3	-	-3.92
2025-01-07	PCVX	87.25	44.3	-	-3.92
2025-01-08	PCVX	81.06	44.3	-	-3.92
2025-01-09	PCVX	81.06	44.3	-	-3.92
2025-01-10	PCVX	81.13	44.3	-	-3.92
2025-01-13	PCVX	81.10	44.3	-	-3.92
2025-01-14	PCVX	78.23	44.3	-	-3.92
2025-01-15	PCVX	89.29	44.3	-	-3.92
2025-01-16	PCVX	87.77	44.3	-	-3.92
2025-01-17	PCVX	85.36	45.5	-	-3.92
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	PCVX	-7.17	13.68	9.17
2024-12-20	PCVX	-7.17	13.68	9.17
2024-12-23	PCVX	-6.98	13.64	9.17
2024-12-24	PCVX	-6.98	13.64	9.17
2024-12-26	PCVX	-6.79	13.64	10.47
2024-12-27	PCVX	-6.70	13.64	10.47
2024-12-30	PCVX	-7.07	12.77	10.47
2024-12-31	PCVX	-7.07	12.77	10.47
2025-01-02	PCVX	-6.71	12.77	10.47
2025-01-03	PCVX	-6.56	12.77	10.47
2025-01-06	PCVX	-6.60	13.64	10.47
2025-01-07	PCVX	-6.60	13.64	10.47
2025-01-08	PCVX	-6.82	13.64	10.47
2025-01-09	PCVX	-6.82	13.64	10.47
2025-01-10	PCVX	-6.72	13.64	10.47
2025-01-13	PCVX	-6.72	13.62	11.90
2025-01-14	PCVX	-6.72	13.62	11.90
2025-01-15	PCVX	-6.72	13.62	11.90
2025-01-16	PCVX	-6.72	13.62	11.90
2025-01-17	PCVX	-6.74	13.62	11.90
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.83

Avg. EPS Est. Current Quarter

-1.01

Avg. EPS Est. Next Quarter

-1.03

Insider Transactions

-6.74

Institutional Transactions

13.62

Beta

0.98

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

29.5

Max Drawdown 5-Year %

Target Price

149.89

P/E

Forward P/E

PEG

P/S

P/B

3.11

P/Free Cash Flow

EPS

-4.68

Average EPS Est. Cur. Y

-3.92

EPS Next Y. (Est.)

-4.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.31

Return on Equity vs Sector %

-33.9

Return on Equity vs Industry %

-21.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

Vaxcyte, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 254

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

stock quote shares PCVX – Vaxcyte, Inc. Stock Price stock today

news today PCVX – Vaxcyte, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch PCVX – Vaxcyte, Inc. yahoo finance google finance

stock history PCVX – Vaxcyte, Inc. invest stock market

stock prices PCVX premarket after hours

ticker PCVX fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: PCVX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y